, Volume 17, Issue 6, pp 471–479

Antimotion Sickness and Antiemetic Drugs

  • Charles D. Wood
Review Article


The antimotion sickness drugs protect a high percentage of individuals from becoming motion sick if the proper drug is given in sufficient dosage 1 to 2 hours before exposure, and an effective blood level is maintained throughout the required period. The stresses due to motion encountered in most civilian travel such as air, automobile and on moderate seas can be counteracted effectively by the antihistaminic group of antimotion sickness preparations. Dimenhydrinate 50mg, cyclizine 50mg, and meclozine 50mg are examples of this group. Doses can be given three times a day during prolonged exposure. If the conditions are more stressful, promethazine 25mg alone or combined with ephedrine 25mg can be given. Highly susceptible patients and very rough conditions may require hyoscine (scopolamine) 0.3 to 0.6mg with or without dexamphetamine 5 to 10mg. Promethazine or hyoscine in the above dose can be given IM as a therapeutic measure after motion sickness has developed, and both produce drowsiness which may be beneficial for the passengers but would be contraindicated for the crew.

All of the antimotion sickness drugs with the exception of dextroamphetamine and ephedrine are effective antiemetics against vomiting of toxic origins. However, the most effective antiemetics in this situation are the phenothiazines such as perphenazine, prochlorperazine and thiethylperazine. Ranking next in effectiveness is trimethobenzamide which is followed by the antihistaminic antimotion sickness drugs. Promethazine ranks with other phenothiazines as an antiemetic and is the only phenothiazine also effective against motion sickness. Morning sickness usually is self limiting but if antiemetics are required, promethazine and dimenhydrinate may be used.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Army, Navy, Air Force Motion Sickness Team: Evaluation of drugs for protection against motion sickness aboard transport ships. Journal of the American Medical Association 160: 755 (1956).Google Scholar
  2. Bennett, I.E.: A review of antiemetic drugs. Journal of the American Podiatry Society 65: 228–232 (1975).Google Scholar
  3. Biggs, J.S.: Vomiting in pregnancy. Causes and management. Drugs 9: 299–306 (1975).PubMedCrossRefGoogle Scholar
  4. Brand, J.J. and Perry, W.L.M.: Drugs used in motion sickness. Pharmacological Reviews 18: 895–924 (1966).PubMedGoogle Scholar
  5. Cockel, R.: Anti-emetics, Practitioner 206: 56–63 (1971).Google Scholar
  6. Graybiel, A. and Johnson, W.H.: A comparison of the symptomatology experienced by healthy persons and subjects with loss of labyrinthine function when exposed to unusual patterns of centripetal force in a counter-rotating room. Annals of Otolaryngology, Rhinology and Laryngology 72: 1–17 (1963).Google Scholar
  7. Hobday, G.R. and Smith, W.G.: A new and effective treatment for acute vertigo and vomiting. Medical Journal of Australia 2: 982–983 (1969).PubMedGoogle Scholar
  8. Lukomskoya, N.Y.; Nikolskay, M.I. and Mikkelson, M.Y.: Search for drugs against motion sickness. Sechenov Institute of Evolutionary Physiology and Biochemistry, Leningrad, USSR (1971).Google Scholar
  9. McMurray, G.N.: Evaluation of metoclopramide as an antiemetic in seasickness. Postgraduate Medical Journal 4: 38–41 (1973).Google Scholar
  10. Money, K.E.: Motion sickness. Physiological Reviews 50: 1–39 (1970).PubMedGoogle Scholar
  11. Reason, J.T. and Brand, J.J.: in Motion Sickness (Academic Press, London 1975).Google Scholar
  12. Turner, A.C.: Motion sickness and travellers diarrhoea. Royal Society of Health Journal 92(3): 146–150 (June 1972).PubMedCrossRefGoogle Scholar
  13. Wood, C.D. and Graybiel, A.: Evaluation of 16 antimotion-sickness drugs under controlled laboratory conditions. Aerospace Medicine 39: 1341 (1968).PubMedGoogle Scholar
  14. Wood, C.D. and Graybiel, A.: A theory of motion sickness based on pharmacological reactions. Clinical Pharmacology and Therapeutics 11: 621 (1970).PubMedGoogle Scholar

Copyright information

© ADIS Press Australasia Pty Ltd 1979

Authors and Affiliations

  • Charles D. Wood
    • 1
    • 2
  1. 1.Louisiana State University School of MedicineShreveportUSA
  2. 2.Naval Aerospace Medical InstitutePensacolaUSA
  3. 3.Department of Pharmacology and TherapeuticsLouisiana State University Medical CenterShreveportUSA

Personalised recommendations